Major adverse cardiovascular events in immune-mediated thrombotic thrombocytopenic purpura during clinical remission

Ítems similars

• Major adverse cardiovascular events in immune-mediated thrombotic thrombocytopenic purpura during clinical remission
  per: Pasquale Agosti, et al.
  Publicat: (2026-06-01)
• Long-term neuropsychological sequelae, emotional wellbeing and quality of life in patients with acquired thrombotic thrombocytopenic purpura
  per: Silvia Riva, et al.
  Publicat: (2020-07-01)
• More on the pathogenesis of thrombotic thrombocytopenic purpura. Comment on “Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism” and on “The different faces of thrombotic thrombocytopenic purpura”
  per: Flora Peyvandi
  Publicat: (2025-01-01)
• Acquired thrombotic thrombocytopenic purpura and HIV infection: a case report and review of the literature
  per: Silvio Rao, et al.
  Publicat: (2026-01-01)
• Risk of relapse after SARS-CoV-2 vaccine in the Milan cohort of thrombotic thrombocytopenic purpura patients
  per: Marco Capecchi, et al.
  Publicat: (2023-03-01)